TP53 and acute myeloid leukemia: Indeed, based on the available preclinical data (24), the finding that none of the five patients without a TP53 mutation achieved CR, and the relatively favorable median OS for TP53-mutated patients in this trial (10 months), TP-0903 seems to be particularly effective in TP53 mutant AML; this implies that the already favorable complete remission rate could have been even better had we only targeted patients with TP53-mutated AML.